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INTRODUCTION
Acute coronary syndromes, including stable angina,
myocardial infarction, both with and without ST segment
elevation and sudden death are responsible for more than
two millions of hospitalizations and 30% of all deaths in the
United States [1,2]. In Brazil, cardiovascular diseases are
the main cause of death; responsible for one-third of all
deaths in the country. According to data based on Death
reported to the DATASUS database of the Brazilian Heath
Ministry, the coefficient of death by cardiovascular diseases
is approximately 442 per 100,000 inhabitants [3]. These
clinical entities are the consequence of atherosclerotic
plaque rupture or significant fissure, with platelet
aggregation and the formation of subocclusive or occlusive
thrombi [1,2]. The rupture of this plaque exposes its central
fat content and causes platelet adhesion and activation of
the coagulation cascade [1,2]. Activated platelets release
diverse vasoactive substances, including thromboxane A2
(TXA) and adenosine diphosphate (ADP) that cause platelet
adhesion and primary hemostasis [1,2]. Secondary
hemostasis occurs as a result of the conversion of the
fibrinogen to fibrin mediated by thrombin and subsequent
stabilization of platelet aggregation [1,2].
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the surface receptors of adjacent platelets, stimulating their
activation. Third, it promotes the action of phospholipase
A2, which is responsible for the production of arachidonic
acid [10,11].
Platelet arachidonic acid is converted to TXA2, in a
reaction catalyzed by the cyclooxygenase-l enzyme (COX-
1) forming prostaglandin G2/H2 and thromboxane synthase
to form TXA2. TXA2 increases the expression of fibrinogen
receptors on the platelet surface and is released into the
circulation, where there is interaction with thromboxane
receptors on the surface of adjacent platelets, stimulating
their respective activation. TXA2 also acts synergically with
other products released by the activated platelets, such as
ADP, fibrinogen and Factor V, intensifying platelet
activation. Moreover, TXA2 is a potent vasoconstrictor
[10,11].
Aspirin (acetylsalicylic acid) reduces platelet activation
through the irreversible acetylation of COX-1 and, thus,
reduces the production of TXA2 by platelets. COX-1
inhibition is rapid, saturable at low-doses, that is, dose-
dependent, irreversible and permanent for the entire life of
the platelet – as it does not present with a biosynthetic
mechanism to synthesize new proteins. After a single 325
mg dose of aspirin, the activity of platelet COX-1 recovers
by approximately 10% per day due to new platelet formation.
Aspirin also has dose-dependent antithrombotic effects on
platelet function and blood coagulation that are not related
to its ability to inhibit platelet COX-1 [12].
Aspirin can also influence hemostasis and
cardiovascular diseases by the independent mechanisms
of prostaglandin (PG) production [1,2]. Although not clearly
defined, the effects of aspirin, which are not mediated by PG
on hemostasis are postulated as being dose-dependent and
not related to the activity of COX-1 [1,2]. These effects
include vitamin K antagonism, reduction in the platelet
production of thrombin and acetylation of one or more
coagulation factors [13]. Aspirin can also harm platelet
function by inhibiting platelet activation mediated by
neutrophils [14]. Additionally, aspirin can potentially alter
the pathogenesis of cardiovascular disease by protecting
low-density lipoproteins from oxidative changes, on
improving endothelial dysfunction in patients with
atherosclerosis and attenuating inflammatory response by
acting as an antioxidant [14].
The anti-inflammatory properties of aspirin are evident,
but not well understood [1,2]. Treatment with aspirin inhibits
endothelial dysfunction mediated by inflammatory
processes, although the mechanism responsible for this
effect is still unknown [15]. Moreover, in normal patients,
therapy with low-doses of aspirin proved to reduce
interleukin 7 released by platelets and thus to reduce the
plasma levels of this cytokine [15]. These observations
In respect to atherothrombotic phenomena, the most
common platelet inhibitor utilized worldwide is aspirin [4,5].
Many studies have demonstrated the efficacy of aspirin in
primary and secondary prevention of myocardial infarction,
strokes and death due to cardiovascular diseases [4,5]. A
recent metanalysis revealed that, among patients with high
vascular risk, therapy with aspirin was associated with a
reduction of 34% of non-fatal myocardial infarction, 25% of
non-fatal strokes and 18% of all causes of death [6].
Atherothrombosis is thus a complex physiological
process and the absolute risk of recurrent vascular events
among patients who take aspirin remains high; estimated at
between 8% and 18% over two years [1,2]. This suggests
that the antiplatelet effects of aspirin may not be
homogeneous for all patients and that multiple therapeutic
agents may be necessary to adequately blockade platelet
function [1,2].
Measurement of platelet aggregation, platelet activation
and bleeding time confirm the variability of the
antithrombotic responses in patients treated with aspirin
[7]. Prospective clinical studies have demonstrated that the
reduction in the response to therapy using aspirin is
associated with an increase in risk of atherothrombotic
events [8,9]. These observations contribute to consolidate
the concept of aspirin resistance, that is, the failure of aspirin
to produce a satisfactory biological response, including
platelet inhibition or the incapacity of aspirin to prevent
atherothrombotic events [1,2]. Moreover, given the
prevalence of cardiovascular diseases, identification and
clinical analysis of patients insensitive to the antiplatelet
effects of aspirin may contribute to the search for alternatives
that achieve appropriate levels of platelet inhibition.
ASPIRIN
Mechanism of action
When the intimal layer of blood vessels is injured, for
example, after injury or rupture of atherosclerotic plaque the
subendothelial collagen and von Willebrand factors enter
the blood circulation. Platelets adhere to the subendothelial
collagen and von Willebrand factors by means of
glycoproteins Ia/IIa and glycoproteins Ib/V/IX receptors.
Platelet adhesion stimulates platelet activation, which causes
changes in the shape of platelets and the release of high
quantities of calcium to enter platelets [10,11].
The increase of free ionized calcium concentrations in
platelets has several consequences. First, it induces a
conformational change in the platelet receptors of the
glycoprotein IIb/IIIa, allowing platelets to bind to adhesive
proteins in the blood circulation, including fibrinogen.
Second, it catalyzes the release of active molecules of platelet
granules into the blood circulation, where they can bind to
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suggest that part of the beneficial effects of aspirin may be
a reduction of vascular inflammation.
Pharmacology
The pharmacological composition of aspirin is
characterized by a rapid absorption in the gastrointestinal
tract with peak plasma concentrations between 30 and 40
minutes after intake [16]. The significant platelet inhibition
effect is observed within 60 minutes of intake and one single
100 mg dose of aspirin completely blocks the production of
TXA2 during the entire life of platelets in most individuals
[16]. The plasma half-life of aspirin is close to 20 minutes,
but the irreversible nature of COX-1 activity inhibition and
the duration of TXA2 suppression demonstrate that the
antithrombotic effects of aspirin are maintained with dose
intervals of from 24 to 48 hours [16].
Randomized studies demonstrate that the benefits of
aspirin therapy are achieved with a broad range of doses
(from 30 to1500 mg per day), but the ideal daily dose has still
not been clearly determined [6,7]. Generally, therapeutic
regimes using high doses are not associated with significant
additional benefits, but, may eventually attenuate the
antithrombotic effects of aspirin and increase the risk of
adverse effects [13].
Measurement of platelet function
To measure platelet function is difficult. In response to
stimuli of platelet activation, they release several chemokines,
cytokines and growth factors in preformed granules;
synthesize prostanoids of arachidonic acid or transform
messenger ribonucleic acids into proteins [1,2]. Apart from
playing an important role in hemostasis, platelets also
participate in inflammatory processes and in systemic
responses to vascular injury [1,2]. In spite of the complex
platelet function, laboratorial methods utilized to quantify
the antithrombotic effects of aspirin are based on the
measurement of platelet aggregation [1,2].
ASPIRIN RESISTANCE
Definition
The term “aspirin resistance” is currently utilized to
describe numerous phenomena, including the inability of
aspirin, to protect patients from thrombotic complications,
to prolong the bleeding time and to inhibit the biosynthesis
of platelet TXA2 [17]. The presence of recurrent vascular
events in some patients however, in spite of prolonged
aspirin therapy, should be denominated therapeutic failure
instead of aspirin resistance, due to the multifactorial nature
of atherothrombosis; only a small fraction of all the vascular
complications can be prevented by one single preventive
strategy [17].
Aspirin resistance, however, may be defined as either
clinical or laboratorial resistance. Clinical resistance is
defined as the failure of aspirin to prevent ischemic
atherothrombotic events in patients with a high risk of
developing cardiovascular and cerebrovascular diseases
[18]. Laboratorial resistance, on the other hand, is the failure
of aspirin to inhibit the production of platelet TXA2 or to
inhibit the platelet function (platelet aggregation) that are
dependent on platelet production of thromboxane [18].
Prevalence
The prevalence of laboratorial aspirin resistance varies
from 5.5% to 61% [18]. Initial evidence that some patients
are resistant to the antiplatelet action of aspirin are from the
study by Mehta et al. [19] in which 30% of patients with
coronary artery disease presented a minimum inhibition of
platelet aggregation after one single 650 mg oral dose of
aspirin. Buchanan et al. [7] already reported that bleeding
time was prolonged in 23 of 40 patients hospitalized for
elective coronary artery bypass grafting surgery, who took
325 mg per day of aspirin, suggesting a prevalence of aspirin
resistance of 57.5%. Recently, Gabriel et al. [20], demonstrated
that 12 of 41 heart disease patients who took daily aspirin
doses of 100 mg as the only platelet antiaggregant drug,
presented values of normal platelet aggregation or
hyperaggregation, identifying aspirin resistance in 29% of
these patients.
This variability of platelet inhibition mediated by aspirin
was not demonstrated only in patients with coronary artery
disease and in those submitted to coronary artery bypass
grafting, but also in normal individuals and those with
cerebrovascular diseases [21]. Despite of the apparent
consistency of these observations, they are not reliable due
to the small sample sizes, the different types of patients
analyzed (variations in age, gender, ethnical background
and clinical conditions), the different definitions of aspirin
resistance, the uncertainty regarding the therapeutic
response to the medication and the lack of compatibility
between the different platelet function tests. The exact
prevalence of aspirin resistance is still unknown.
Clinical relevance
The clinical observations suggest a causal relationship
between aspirin resistance and cardiovascular risk [1,2]. One
of the first works that demonstrated an association between
the laboratorial measurement of aspirin resistance and the
risk of severe vascular events was a cohort study of 181
stroke patients treated with high doses of aspirin (500 mg
three times per day). In this research, an incidence of 30% of
aspirin resistance was reported [22]. Grundmann et al. [23]
found a significantly higher incidence of aspirin resistance
(34%) among patients who had previously suffered from
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strokes or ischemic events, when compared to asymptomatic
patients with cerebrovascular disease. Among patients with
intermittent claudication submitted to peripheral vascular
angioplasty, Mueller et al. [24] reported an incidence of 40%
aspirin resistance with aspirin resistance being associated
with an 87% increase in risk of future arterial occlusion after
18 months of clinical follow-up. In 2003, Gum et al. [9]
reported on a cohort of 326 patients with cerebrovascular
and coronary artery diseases, treated with 325 mg of aspirin
per day who were clinically followed-up for two years. Of
the 17 (5%) patients diagnosed with aspirin resistance, five
(29%) suffered from serious vascular events in this period.
Recently, Chen et al. [8] reported an association between
aspirin resistance and creatine-kinase MB elevation after
percutaneous coronary artery procedures.
In 151 patients with stable coronary artery disease, the
incidence of aspirin resistance was 19.2%. Moreover,
researchers of the PURSUIT study reported that previously
taking aspirin is an independent predictor of increased
cardiovascular risk among patients with acute coronary
syndromes [25]. Of 9461 patients, those that had previously
taken aspirin presented a 20% higher risk of suffering
recurrent events in the following six months than those that
had not utilized the medication [25].
Although widely utilized in primary and secondary
prevention of cardiovascular events and in the management
of patients submitted to coronary artery bypass grafting
surgery, the ideal daily dose recommended for aspirin
therapy has not been clearly elucidated yet. In 2001, the
Brazilian Guidelines on Dyslipidemia and Prevention of
Atherosclerosis [26] recommended doses of aspirin of
greater than 100 mg per day for individuals who present
with high risk for cardiovascular events (secondary
prevention, diabetics or absolute risk of coronary events =
20% over 10 years) and those who do not present with
contra-indications – degree of recommendation A and level
of evidence 1. The guidelines in coronary artery bypass
grafting, heart valve defect and aortic disease surgeries [27]
recommend that patients submitted to coronary artery
bypass grafting in acute coronary syndromes should take
aspirin at doses of from 100 to 325 mg per day, starting in the
first 24 postoperative hours and continuing indefinitely. In
cases of aspirin intolerance, 250 mg per day of ticlopidine is
recommended. On the other hand, guidelines for chronic
coronary disease and stable angina [28], affirm that all
individuals with stable angina must take aspirin, but the
guidelines do not specify an ideal daily dose.
Despite the recommended dose of aspirin varying (from
30 to 1500 mg/day), with antiplatelet therapeutic indications
for several clinical entities, such as heart arrhythmias, acute
coronary syndromes, cerebrovascular diseases and
peripheral vascular diseases, it is well known that for 5% to
45% of patients, aspirin does not produce antiplatelet effects
and atherothrombotic events recur. Thus, further research
is essential with the aim of establishing specific parameters
that contribute to the indication of an effective dose for
platelet antiaggregation. Moreover, the development of
adequate techniques to measure the efficiency of aspirin as
an antiplatelet agent will help to reduce recurrent vascular
events following the use of aspirin.
Potential mechanisms of aspirin resistance
In spite of current knowledge related to the antiplatelet
effects of aspirin, the mechanisms by which some patients
are resistant are not clearly established yet [1,2]. The answer
for this is probably a combination of genetical, biological
and clinical aspects, that directly and indirectly affect platelet
function (Table 1) [1,2]. From the clinical perspective, habits
such as smoking, compliance with prescribed therapy, drug
interactions for example with non-hormonal anti-
inflammatory agents, and length of treatment with aspirin
can contribute to individual differences regarding response
to antiaggregation effects [1,2]. Although smoking has been
identified by some researchers as a potent platelet activator
and intensifier of thrombogenesis mediated by platelets,
even with the suppression of TXA2 by aspirin, these
observations are not consistent, showing the necessity of
more research to study the influence of smoking on aspirin
resistance [29]. Some researchers affirm that the increase in
risk of recurrent vascular events in patients who take aspirin
can be primarily explained by non-compliance to treatment.
Cotter et al. [30] reported that among 73 patients who used
aspirin on a daily basis after myocardial infarction, the
percentage of adverse events such as sudden death,
myocardial infarction or unstable angina over 12 months,
was greater among patients who were considered non-
compliers to treatment (42%) compared to those who were
considered compliers (6%) or biologically resistant (11%).
The role of non-hormonal anti-inflammatory drugs in the
attenuation of the long-term antithrombotic benefits of
aspirin has been reported, but this remains controversial
[31]. Non-selective non-hormonal anti-inflammatory drugs
have a strong affinity to a specific area of platelet COX-1
and may prevent aspirin mediated acetylation. However,
recent studies are not consistent or definitive in providing
clinical relevance to this potential interaction [1,2,31].
The length of therapy may also contribute to the lack of
response to aspirin. Pulcinelli et al. [32] recently reported
the effects of 2, 6, 12 and 24 months of aspirin treatment (100
or 330 mg per day) on ADP and platelet aggregation induced
by collagen, among 150 patients with clinical evidence of
atherothrombosis. In spite of adequate platelet inhibition
after two months of treatment, over the long-term, treatment
with aspirin was associated with a progressive reduction in
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sensitivity to its effects [32]. The researchers also affirmed
that the sensitivity to aspirin is not dose-dependent, in
agreement with previous observations.
The different mechanisms of platelet activation and the
receptors involved may also contribute to the genesis of
aspirin resistance. More specifically, mechanisms involving
the non-dependent platelet activators of TXA2, such as
thrombin, ADP, epinephrine and collagen, may prevent the
aspirin mediated inhibitory effect leading to platelet
activation and thrombosis. Platelet aggregation induced by
catecholamines is, for example, one of the pathways that
may not be adequately inhibited by aspirin [1,2].
Table 1 – Potential Mechanisms of Aspirin Resistance
COX = cyclooxygenase; TXA2 = thromboxane A2
Adapted from Mason et al. [1]
CLINICAL
1. Smoking: increases platelet function
2. Lack of compliance to aspirin therapy
PHARMACODYNAMICS
1. Length of therapy: the biological response to aspirin may be reduced in long-term therapy.
2. Medicinal interactions: non-hormonal anti-inflammatory drugs may inhibit aspirin-mediated acetylation of
COX-1 and attenuate the long-term antithrombotic effects of aspirin.
3. Dose-dependency: The antiplatelet and anti-inflammatory effects of aspirin may be dose-dependent.
BIOLOGICAL
1.  Lack of sensitivity of aspirin to TXA2 biosynthesis: the activity induced by COX-2 or regeneration of COX-
1 in macrophages and endothelial vascular cells may increase TXA2 production.
2. Alternative pathways of platelet activation;
a. Failure to inhibit platelet activation mediated by catecholamines, such as with physical exercise and mental stress.
b. Failure to inhibit platelet activation, not mediated by TXA2, such as by diphosphate adenosine, platelet
activation factor and thrombin.
c. Increase in the sensitivity to collagen in patients who do not respond to aspirin, may lead to an increase in
platelet adhesion.
3. Compositions similar to aspirin: isoprostanes are produced from arachidonic acid and fat peroxidation and
may present proprieties similar to TXA2.
4. Vascular inflammation: the increase in the expression of the CD40 receptor on the platelet surface may represent
a new pathway to platelet activation or a connection between vascular inflammation and platelet activity.
GENETICS
1. Mutations and/or polymorphisms of the COX-1 gene may prevent aspirin-mediated COX-1 acetylation.
2. Polymorphisms of glycoprotein IIb/IIIa ( PIA2) receptors
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Hurlen et al. [33] reported that, among myocardial
infarction patients, aspirin achieved satisfactory antiplatelet
effects during resting, but failed to inhibit the increase of
platelet aggregation induced by exercise. This observation
suggests that the antiplatelet effects of aspirin can be
surpassed over periods of increased activity of the
sympathetic nervous system, such as during exercise or
physical stress. Moreover, patients that do not respond to
aspirin may present an increase of platelet sensitivity with
collagen [34].
Alternative pathways of TXA2 synthesis and the
identification of components similar to prostaglandin
(isoprostane) also provide potential explanations of aspirin
resistance syndrome. The biosynthesis of TXA2 that is not
sensitive to aspirin may occur as a result of COX-2 induction
in non-platelet cells (monocytes/macrophages or endothelial
cells), resulting from a local inflammatory stimulus [35]. These
cells can also release TXA2 or supply their respective
precursor, PGH2, for platelet inhibition by aspirin. Moreover,
COX-2 is present in newly-formed platelets and may
contribute to the detectable levels of TXA2 synthesis during
periods of platelet turnover [14]. Isoprostanes from fat
peroxidation circulate in high concentrations in patients with
unstable angina, diabetes mellitus and hyperlipidemia and
in smokers. Moreover, acting as vasoconstrictors,
isoprostanes may play a role in the amplification of platelet
response to other agonists [13].
The interaction of the platelets with other cells, such as
the red blood cells or vascular endothelial cells, may also
affect aspirin-mediated inhibition. It has been demonstrated,
for example, that red blood cells induce an increase in the
platelet synthesis of TXA2 and release of serotonin, beta-
thromboglobulin, and ADP. Previous investigations among
patients with vascular diseases demonstrated that aspirin
(200 to 300mg per day) incompletely blocks platelet reactivity
in more than two-thirds of patients due to erythrocytes, in
spite of an adequate inhibition of platelet TXA2 synthesis
[17,18]. The increase in monocyte aggregation to circulating
platelets during acute atherothrombotic events represents
a link between inflammatory processes and thrombosis.
There is evidence that interactions between CD40-CD40
receptors may play an important role in platelet activation,
arterial thrombosis and in the pathways of platelet-mediated
vascular inflammation [36].
Finally, aspirin resistance may also be explained, in
part, by genetical differences in COX-1 genes or in the
complex glycoprotein IIb/IIIa receptors. Polymorphisms
of the IIIa subunit have been identified and specific
alleles, PlA1/A2 and PlA2/A2, are associated with an increase
in thrombin formation and there is a low threshold of
platelet activation, alpha granule release and fibrinogen
binding [35]. Although not confirmed yet, it has been
suggested that mutations or polymorphisms of COX-1
genes may also help to explain the structural basis of
aspirin resistance in some patients [35].
Treatment of aspirin resistance
The best manner to treat aspiring resistance and,
thus, to improve the efficacy of aspirin in preventing
atherothrombotic vascular  events,  consists  in
identifying and treating the aspect responsible for
aspirin resistance [18].
Adequate therapeutic alternatives include the
identification and treatment of non-atherothrombotic causes
of vascular events, that will probably not respond to aspirin,
such as for example, antibiotics for infectious endocarditis
and corticoids for arteritis; improvement in the therapeutic
compliance of patients to aspirin treatment; avoid the use
of medications that may adversely interact with aspirin, such
as ibuprofen; cease smoking; increase the frequency of
aspirin administration and substitute or associate aspirin
with other antiplatelet agents capable of inhibiting other
pathways responsible for platelet activation, such as
blocking ADP receptors, thromboxane receptor antagonists
or the common final pathway of platelet aggregation, such
as blocking intravenous glycoprotein IIb/IIIa receptors
[17,18].
However, although these therapeutic alternatives seem
sufficient, they are not necessarily effective and safe. For
example, an increase in the aspirin dose in order to increase
platelet COX-1 suppression seems logical, but evidence
shows that low doses of aspirin are as efficient as high
doses in the prevention of cardiovascular events [18].
Moreover, randomized studies state that the addition of
clopidogrel to aspirin therapy, in patients with acute
coronary syndromes or submitted to percutaneous coronary
interventions, improves the results without increased
danger [37].
Thus, further research is necessary to determine the
effectiveness and safety of other alternative therapies for
aspirin resistance, as well as to identify factors that are
associated to favorable or unfavorable responses.
CONCLUSION
Aspirin resistance remains a highly prevalent
phenomenon in patients who require antithrombotic
treatment and represents a biological aspect with significant
clinical implications. It is important to mention that
laboratorial measurement showing lack of antiaggregation
effects to aspirin is a predictor of increased risk for future
atherothrombotic events.
The main doubts that still need to be studied further in
relation to aspirin are:
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1. The lack of a standardized definition and a valid method
to identify aspirin resistance;
2. The unknown prevalence of aspirin resistance in the
population;
3. To identify clear biological mechanisms of aspirin
resistance;
4. The incomplete understanding of adequate
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its activity;
5. The absence of a proven therapeutic strategy for
affected individuals.
In spite of resistance to the antithrombotic effects of
aspirin, this medicine continues to participate as a powerful
therapy against atherothrombotic complications in
cardiovascular diseases.
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